ArticleAmerican journal of translational research2026
Dynamic evaluation of serum atherogenic factors as a predictor of QT interval prolongation in patients with type 2 diabetes mellitus.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the correlation between dynamic changes in serum atherogenic factors and QT interval prolongation in type 2 diabetes mellitus (T2DM) patients, and evaluate its clinical application value.
methodsA single-center retrospective analysis was conducted on 613 T2DM patients, who met the 2011 American Diabetes Association criteria, at Nantong Hospital to Nanjing University of Chinese Medicine. Clinical data, atherogenic lipid profiles, inflammatory factors, and endothelial function indicators were collected. All patients underwent 12-lead electrocardiography to measure corrected QT interval (QTc) at baseline and after 12-month follow-up. Repeated measures ANOVA was used to compare indicator dynamics between patients with new-onset QT prolongation and non-prolongation groups, followed by multivariate logistic regression and ROC curve analyses.
resultsDuring follow-up, 32 (5.2%) patients developed QT prolongation. Baseline diabetes duration, HbA1c, atherogenic lipid indices (e.g., TG/HDL-C ratio), hs-CRP, IL-6, ET-1 and vWF were significantly higher, while HDL-C and NO were lower in the prolongation group (all P<0.05). These factors correlated with QTc. Multivariate regression identified TG/HDL-C ratio, hs-CRP, ET-1 and IL-6 as independent risk factors, with TG/HDL-C ratio showing the highest risk. Combined detection of these indicators yielded superior predictive value for QT prolongation over single indicators (P<0.05).
conclusionAbnormal atherogenic lipids, inflammatory factors and endothelial markers correlate with QT interval prolongation in T2DM. Combined detection of TG/HDL-C ratio, hs-CRP, IL-6 and ET-1 enhances the predictive efficacy for QT prolongation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.